6 stocks to buy in this correction for gains of up to 37% in 1 year


oi-Roshni Agarwal


Concerns over the new variant of Covid collapsed significantly last week and trade on November 30, 2021 is currently down almost 8.5% from its all-time high of 18,604 scaled on October 19 2021. Markets around the world have already taken into account a rate hike earlier than expected by the US Federal Reserve in a context of inflationary peaks.

“Due to various global factors (announcement of Fed cut, rising bond yields, rising crude oil prices and strengthening of the US dollar index) and the detection of a new variant of COVID-19 – Omicron – in South Africa Nifty fell sharply. Significant fundraising in the primary market also put some pressure on the secondary market. Sentiments were beaten globally, with global markets correcting 2-3%, bond yields eased and Brent crude prices fell 11%. 20.8.

Since these are the early days of the new variant, limited information regarding its transmission and impact is available. We expect Central / State governments to remain proactive, given their experience with the second wave of COVID in April-May’21, and guidelines will evolve as the trajectory of the new variant becomes clearer. We expect the market to experience high volatility in the near term. However, post-pullback valuations are now relatively reasonable at 23.3x / 19.5x FY22E / FY23E Nifty EPS. Therefore, we advise investors to buy this correction. advise investors to adhere to this correction, ”said Mr. Siddhartha Khemka, Head of Retail Research, Motilal Oswal Financial Services Ltd.

Likewise, different brokerages have offered ‘Buy’ recommendations from different sectors for huge gains over a one year period:

1. UPL:

1. UPL:

Jefferies has a “Buy” on the UPL script for a target price of Rs over 1 year. 945. The “Buy” was chosen given the various triggers, including the emphasis on differentiated accretive solutions, robust pricing, launch of new platforms and ESG that could support its future growth.

2. IPCA laboratory:

Motilal Oswal has a “Buy” call on the pharmaceutical certificate for a 1 year price target of Rs. 2,600. Brokerage is bullish over the counter given superior execution in branded generic exports, expansion of API capacity and improved traction in the institutional antimalarial segment.

3. Infratech PNC:

3. Infratech PNC:

This real estate construction and procurement entity received a tender from Geojit for a price target of Rs. 370 to be achieved in 1 year. The buy on the share was repeated given the strong order book and a healthy balance sheet. The company’s second-quarter revenue, which grew 53% year-over-year in the second quarter, was better than estimates.

4. Escorts:

Emkay has given a purchase on the major tractor for a target price of Rs. 2,140 over the 1 year horizon. The share was reclassified as “Buy” as the takeover of Kubota would significantly improve the company’s medium-term growth prospects; through technology support and using Escorts to meet Kubota’s global component needs.

5. Dixon Technologies:

5. Dixon Technologies:

The power company was again upgraded to a “Buy” by Anand Rathi for a price target of Rs 1 year. 5936. Having established itself in Indian subcontracting, Dixon has global aspirations and is now targeting the global LED bulb market.

6. Blue Dart Express:

Nirmal Bang maintained its call to buy from the courier company for a price target of Rs. 7,776 each. According to the brokerage, the company’s market share has gained up to 25% despite higher prices compared to its peers due to an unbeatable record in safety and reliability.

StoreBrokerage companyCourse objective at 1 yearLast price traded on November 30, 2021Upside potential
IPCAMotilal Oswal2600211623.00%
Infratech PNCGeojit37029924.00%
DixonAnand Rathi5936506817.00%
Bluedart ExpressNirmal Bang7776673715.00%


The above stocks from different sectors are recommended by different brokerage houses for potential gains. Investing in stocks presents a risk of financial loss. Investors should therefore exercise caution. Greynium Information Technologies, the author and the brokerage are not responsible for any losses caused as a result of decisions based on the article.

Source link

Comments are closed.